Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Emerilis
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Emerilis is a pharmaceutical medication containing tadalafil, a potent and selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It is a generic version of the brand-name drug Cialis and is primarily indicated for the treatment of erectile dysfunction (ED) in adult men. By inhibiting the PDE5 enzyme, tadalafil prevents the degradation of cGMP in the smooth muscle cells of the corpus cavernosum. This leads to prolonged smooth muscle relaxation and increased blood flow into the penile tissues, which facilitates an erection in response to sexual stimulation. Tadalafil is distinguished from other PDE5 inhibitors by its relatively long half-life, providing a duration of action of up to 36 hours. Emerilis is developed and marketed by Lek, a subsidiary of Sandoz (Novartis).
- Brand names
- Emerilis
- Other names
- tadalafil
02
Targets
TUBB (Tubulin (alpha and beta subunits))MET (Mesenchymal-epithelial transition factor receptor)PDE5 (Phosphodiesterase 5A)
Beyond the preview
Go deeper on Emerilis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Emerilis.